Total Payments
$780,027
2024 Payments
$82,885
Companies
51
Transactions
1,258
Medicare Patients
1,353
Medicare Billing
$180,835
Payment Breakdown by Category
Other$475,847 (61.0%)
Consulting$148,540 (19.0%)
Travel$88,274 (11.3%)
Research$47,439 (6.1%)
Food & Beverage$19,629 (2.5%)
Education$296.96 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $311,853 | 120 | 40.0% |
| Honoraria | $163,994 | 69 | 21.0% |
| Consulting Fee | $148,540 | 66 | 19.0% |
| Travel and Lodging | $88,274 | 318 | 11.3% |
| Unspecified | $47,439 | 22 | 6.1% |
| Food and Beverage | $19,629 | 657 | 2.5% |
| Education | $296.96 | 6 | 0.0% |
Payments by Type
General
$732,587
1,236 transactions
Research
$47,439
22 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ACADIA Pharmaceuticals Inc | $192,718 | 250 | $0 (2024) |
| Kyowa Kirin, Inc. | $114,533 | 88 | $0 (2024) |
| Amneal Pharmaceuticals LLC | $86,857 | 120 | $0 (2024) |
| Adamas Pharmaceuticals, Inc. | $84,056 | 105 | $0 (2021) |
| MDD US Operations, LLC | $68,794 | 83 | $0 (2024) |
| US WorldMeds, LLC | $47,999 | 120 | $0 (2020) |
| Eli Lilly and Company | $45,334 | 11 | $0 (2023) |
| Acorda Therapeutics, Inc | $39,464 | 66 | $0 (2023) |
| Neurocrine Biosciences, Inc. | $39,129 | 83 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $20,826 | 28 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $82,885 | 153 | Amneal Pharmaceuticals LLC ($24,450) |
| 2023 | $104,845 | 227 | ACADIA Pharmaceuticals Inc ($43,528) |
| 2022 | $113,892 | 191 | Kyowa Kirin, Inc. ($40,744) |
| 2021 | $68,970 | 140 | Kyowa Kirin, Inc. ($44,544) |
| 2020 | $68,591 | 96 | Kyowa Kirin, Inc. ($20,806) |
| 2019 | $196,687 | 274 | Adamas Pharmaceuticals, Inc. ($53,481) |
| 2018 | $103,601 | 119 | ACADIA Pharmaceuticals Inc ($29,675) |
| 2017 | $40,554 | 58 | ACADIA Pharmaceuticals Inc ($22,098) |
All Payment Transactions
1,258 individual payment records from CMS Open Payments — Page 1 of 51
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $5,452.50 | General |
| 12/17/2024 | ABBVIE INC. | VYALEV (Drug) | Consulting Fee | Cash or cash equivalent | $1,600.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/17/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $186.49 | General |
| 12/16/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $24.95 | General |
| Category: Neuropsychiatry | ||||||
| 12/05/2024 | ABBVIE INC. | VYALEV (Drug) | Food and Beverage | In-kind items and services | $72.57 | General |
| Category: NEUROSCIENCE | ||||||
| 11/26/2024 | Merz Pharmaceuticals, LLC | AMPYRA (Drug) | Food and Beverage | In-kind items and services | $31.15 | General |
| Category: Multiple Sclerosis | ||||||
| 11/15/2024 | ABBVIE INC. | VYALEV (Drug) | Food and Beverage | In-kind items and services | $22.71 | General |
| Category: NEUROSCIENCE | ||||||
| 11/06/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $42.34 | General |
| Category: Central Nervous System | ||||||
| 10/31/2024 | ABBVIE INC. | VYALEV (Drug) | Food and Beverage | In-kind items and services | $26.60 | General |
| Category: NEUROSCIENCE | ||||||
| 10/31/2024 | Merz Pharmaceuticals, LLC | INBRIJA (Drug), AMPYRA | Food and Beverage | In-kind items and services | $20.97 | General |
| Category: Parkinson's Disease | ||||||
| 10/24/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $15.18 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 10/14/2024 | ABBVIE INC. | VYALEV (Drug) | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| Category: NEUROSCIENCE | ||||||
| 10/14/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Food and Beverage | In-kind items and services | $80.44 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 10/08/2024 | Merz Pharmaceuticals, LLC | AMPYRA (Drug), INBRIJA | Food and Beverage | In-kind items and services | $31.31 | General |
| Category: Multiple Sclerosis | ||||||
| 10/01/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $19.25 | General |
| Category: Central Nervous System | ||||||
| 09/29/2024 | ABBVIE INC. | VYALEV (Drug) | Food and Beverage | In-kind items and services | $48.81 | General |
| Category: NEUROSCIENCE | ||||||
| 09/23/2024 | ABBVIE INC. | DUOPA (Drug) | Food and Beverage | In-kind items and services | $28.63 | General |
| Category: NEUROSCIENCE | ||||||
| 09/19/2024 | Merz Pharmaceuticals, LLC | Xeomin (Biological) | Food and Beverage | In-kind items and services | $33.87 | General |
| Category: Musculoskeletal | ||||||
| 09/13/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | In-kind items and services | $21.56 | General |
| Category: Neuroscience | ||||||
| 09/11/2024 | UCB, Inc. | Fintepla (Drug) | Food and Beverage | In-kind items and services | $19.40 | General |
| Category: Neurology | ||||||
| 09/07/2024 | MDD US Operations, LLC | Gocovri (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,740.00 | General |
| Category: AMANTADINE | ||||||
| 09/07/2024 | MDD US Operations, LLC | Gocovri (Drug) | Travel and Lodging | In-kind items and services | $44.74 | General |
| Category: AMANTADINE | ||||||
| 09/07/2024 | MDD US Operations, LLC | Gocovri (Drug) | Travel and Lodging | In-kind items and services | $41.95 | General |
| Category: AMANTADINE | ||||||
| 09/05/2024 | Kyowa Kirin, Inc. | Nourianz (Drug) | Food and Beverage | In-kind items and services | $10.72 | General |
| Category: Adenosine A2A Receptors | ||||||
| 08/23/2024 | Amneal Pharmaceuticals LLC | RYTARY (Drug) | Food and Beverage | In-kind items and services | $9.08 | General |
| Category: NEUROLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| EFFECT OF LY3154207 ON COGNITION IN MILD TO MODERATE PARKINSONS DISEASE DEMENTIA PDD - THE PRESENCE STUDY | Eli Lilly and Company | $42,689 | 3 |
| Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease | Biogen, Inc. | $2,036 | 8 |
| ACP-103-048 | ACADIA Pharmaceuticals Inc | $1,570 | 8 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $734.00 | 2 |
| A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | Eli Lilly and Company | $410.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 252 | 483 | $105,328 | $40,144 |
| 2022 | 5 | 288 | 522 | $111,006 | $42,091 |
| 2021 | 6 | 337 | 583 | $125,957 | $48,970 |
| 2020 | 9 | 476 | 825 | $154,771 | $49,630 |
Total Patients
1,353
Total Services
2,413
Medicare Billing
$180,835
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 158 | 340 | $64,940 | $24,702 | 38.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 60 | 85 | $22,950 | $9,575 | 41.7% |
| 64611 | Injection of chemical for paralysis of salivary glands on both sides of mouth | Facility | 2023 | 18 | 42 | $10,878 | $3,620 | 33.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 16 | 16 | $6,560 | $2,247 | 34.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 170 | 343 | $65,983 | $25,794 | 39.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 71 | 98 | $26,500 | $10,202 | 38.5% |
| 64611 | Injection of chemical for paralysis of salivary glands on both sides of mouth | Facility | 2022 | 17 | 37 | $9,583 | $3,207 | 33.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 19 | 19 | $7,790 | $2,516 | 32.3% |
| 95970 | Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator | Facility | 2022 | 11 | 25 | $1,150 | $370.80 | 32.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 170 | 342 | $65,322 | $25,330 | 38.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 79 | 107 | $28,890 | $12,668 | 43.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 52 | 52 | $21,320 | $7,870 | 36.9% |
| 64611 | Injection of chemical for destruction of salivary glands on both sides of the mouth | Facility | 2021 | 14 | 31 | $8,029 | $2,360 | 29.4% |
| 95874 | Needle measurement and recording of electrical activity of muscles for guidance with injection of chemical for destruction of muscles | Facility | 2021 | 11 | 25 | $1,200 | $381.92 | 31.8% |
| 95970 | Electronic analysis of implanted brain, spinal cord or peripheral stimulation device | Facility | 2021 | 11 | 26 | $1,196 | $361.24 | 30.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 173 | 335 | $66,755 | $20,088 | 30.1% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 102 | 156 | $43,503 | $13,981 | 32.1% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 31 | 31 | $13,070 | $4,081 | 31.2% |
| 99490 | Chronic care management services at least 20 minutes per calendar month | Facility | 2020 | 73 | 139 | $10,564 | $3,887 | 36.8% |
| 64611 | Injection of chemical for destruction of salivary glands on both sides of the mouth | Facility | 2020 | 20 | 40 | $10,080 | $3,169 | 31.4% |
| 99487 | Complex chronic care management services 60 minutes clinical staff time | Facility | 2020 | 31 | 44 | $5,544 | $2,020 | 36.4% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 17 | 17 | $1,613 | $1,160 | 71.9% |
| 99489 | Complex chronic care management services each additional 30 minutes clinical staff time | Facility | 2020 | 18 | 37 | $2,368 | $839.61 | 35.5% |
| 95874 | Needle measurement and recording of electrical activity of muscles for guidance with injection of chemical for destruction of muscles | Facility | 2020 | 11 | 26 | $1,274 | $403.39 | 31.7% |
About Dr. Pinky Agarwal, MD
Dr. Pinky Agarwal, MD is a Specialist healthcare provider based in Kirkland, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/24/2005. The National Provider Identifier (NPI) number assigned to this provider is 1245223296.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Pinky Agarwal, MD has received a total of $780,027 in payments from pharmaceutical and medical device companies, with $82,885 received in 2024. These payments were reported across 1,258 transactions from 51 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($311,853).
As a Medicare-enrolled provider, Agarwal has provided services to 1,353 Medicare beneficiaries, totaling 2,413 services with total Medicare billing of $180,835. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Other Specialties Neurology
- Location Kirkland, WA
- Active Since 08/24/2005
- Last Updated 01/26/2010
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1245223296
Products in Payments
- NUPLAZID (Drug) $192,718
- GOCOVRI (Drug) $112,924
- NOURIANZ (Drug) $106,217
- RYTARY (Drug) $74,039
- INBRIJA (Drug) $39,204
- INGREZZA (Drug) $33,115
- APOKYN (Drug) $26,097
- Gocovri (Drug) $16,894
- NORTHERA (Drug) $14,090
- MYOBLOC (Biological) $12,739
- Xadago (Drug) $8,675
- Nourianz (Drug) $8,316
- Ongentys (Drug) $5,785
- KYNMOBI (Drug) $3,050
- VYALEV (Drug) $2,608
- Dhivy (Drug) $1,844
- APTIOM (Drug) $1,604
- DUOPA (Drug) $1,293
- BOTOX (Biological) $1,136
- Dysport 300 U-1 (Drug) $794.94
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Kirkland
Mrs. Angela Negron Fulton, Pa-C, PA-C
Specialist — Payments: $84,015
Specialist $84,015
Dr. Sunil Ummat, Md, MD
Specialist — Payments: $6,247
Specialist $6,247
Dr. Ronald Gregush, M.d, M.D
Specialist — Payments: $4,461
Specialist $4,461
Pamila Keech, Md, MD
Specialist — Payments: $4,421
Specialist $4,421
Dr. Bradley Remington, M.d, M.D
Specialist — Payments: $4,144
Specialist $4,144
Dr. Maher Anous, M.d, M.D
Specialist — Payments: $697.26
Specialist $697.26